Evaxion Biotech Completes Dosing In Phase 2 Trial For Personalized Cancer Vaccine EVX-01

(RTTNews) - Evaxion Biotech A/S (EVAX), a clinical-stage TechBio company specializing in AI-driven vaccines, has announced the completion of dosing for all 16 patients in its Phase 2 trial of EVX-01, its lead asset. EVX-01, a personalized cancer vaccine designed using Evaxion's AI-Immunology platform, is being developed as a treatment for advanced melanoma, a form of skin cancer.

The dosing process has been completed according to the trial protocol and timeline, keeping the trial on track for its scheduled data readout in the second half of 2025. Notably, the first patient has completed their participation in the trial and attended their final visit, in line with the trial's protocol. Ongoing monitoring and data collection will continue for the remaining patients.

As the trial progresses, the company remains hopeful that EVX-01 could provide a breakthrough treatment for melanoma, one of the most common and aggressive forms of skin cancer.

EVAX is currently trading at $3.48 down 6.45 percent or $0.24 on the Nasdaq.